{
    "nctId": "NCT00369655",
    "briefTitle": "VEGF Trap in Treating Patients With Metastatic Breast Cancer",
    "officialTitle": "Phase II Trial of VEGF Trap in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline and/or Taxane",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 21,
    "primaryOutcomeMeasure": "Proportion of Patients With Confirmed Tumor Response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed adenocarcinoma of the breast\n\n  * Clinical evidence of metastatic disease\n* No more than 2 prior chemotherapy regimens for metastatic disease\n\n  * Prior neoadjuvant or adjuvant chemotherapy allowed\\*\n  * At least 1 prior regimen (in any setting) must have included a taxane and/or an anthracycline\n* Measurable disease, defined as \u2265 1 lesion whose longest diameter can be accurately measured per RECIST criteria\n\n  * No nonmeasurable disease, defined as all other lesions, including small lesions(longest diameter \\< 20 mm) and truly nonmeasurable lesions, including the following:\n\n    * Bone lesions\n    * Leptomeningeal disease\n    * Ascites\n    * Pleural/pericardial effusion\n    * Inflammatory breast disease\n    * Lymphangitis cutis/pulmonis\n    * Abdominal masses that are not confirmed and followed by imaging techniques\n    * Cystic lesions\n* Patients with HER2-positive tumors (3+ by immunohistochemistry or amplified by fluorescent in situ hybridization \\[FISH\\]) must have received \u2265 1 prior trastuzumab (Herceptin\u00ae)-containing regimen in either the adjuvant or metastatic setting, unless there was a contraindication\n* No known CNS metastases\n* No evidence of leptomeningeal involvement\n* Hormone receptor status not specified\n* Male or female\n* Menopausal status not specified\n* ECOG performance status 0-1\n* Life expectancy \\> 3 months\n* WBC \u2265 3,000/mm\u00b3\n* Absolute neutrophil count \u2265 1,500/mm\u00b3\n* Platelet count \u2265 75,000/mm\u00b3\n* Hemoglobin \\> 8.0 g/dL\n* Bilirubin \u2264 1.5 times upper limit of normal (ULN)\n* Alkaline phosphatase \u2264 3 times ULN\n* AST and ALT \u2264 2.5 times ULN\n* Creatinine \u2264 1.5 times ULN\n* Urine protein:creatinine ratio \\< 1 OR urine protein \\< 500 mg by 24-hour urine collection\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for 6 months after completion of study treatment\n* No significant traumatic injury within the past 4 weeks\n* No history of allergy or hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies, drug product excipients, or agents chemically or biologically similar to VEGF Trap\n* No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days\n* No nonhealing wound, fracture, or ulcer\n* No stage III or IV invasive, nonbreast malignancy within the past 5 years\n* No history of lung carcinoma of squamous cell type\n* No clinically significant cardiovascular disease, including any of the following:\n\n  * Cerebrovascular accident or stroke within the past 6 months\n  * Uncontrolled hypertension, defined as blood pressure (BP) \\> 150/100 mm Hg OR systolic BP \\> 180 mm Hg if diastolic blood pressure \\< 90 mm Hg on \u2265 2 separate occasions within the past 3 months\n  * Myocardial infarction, coronary artery bypass graft, or unstable angina within the past 6 months\n  * New York Heart Association class III or IV cardiovascular disease\n  * Serious cardiac arrhythmia requiring medication\n  * Peripheral vascular disease \u2265 grade 2 within the past 6 months\n  * Pulmonary embolism, deep vein thrombosis, or other thromboembolic event within the past 6 months\n* No evidence of bleeding diathesis or uncontrolled coagulopathy\n* No active, unresolved infection\n* No serious concurrent medical condition that would preclude study participation\n* No other condition or circumstance that would preclude compliance with study requirements\n* See Disease Characteristics\n* Prior hormonal therapy in the neoadjuvant, adjuvant, or metastatic setting allowed\n* No prior bevacizumab\n* More than 4 weeks since prior chemotherapy, endocrine therapy, experimental drug therapy, or immunotherapy and recovered\n* More than 4 weeks since prior major surgery or open biopsy\n* More than 7 days since prior core biopsy\n* More than 2 weeks since prior radiotherapy, except if to a nontarget lesion only\n\n  * Prior radiotherapy to a target lesion allowed only if there has been clear progression of the lesion since radiotherapy was completed\n  * Prior single-dose palliative radiotherapy within the past 2 weeks allowed\n* No concurrent major surgery\n* No concurrent trastuzumab\n* Concurrent full-dose anticoagulants (e.g., warfarin) with PT INR \\> 1.5 allowed provided the following criteria are met:\n\n  * INR in-range (usually between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin\n  * No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)\n* No concurrent combination antiretroviral therapy for HIV-positive patients\n* No concurrent participation in another investigational clinical trial\n* No other concurrent chemotherapeutic agents, endocrine therapy, biologic agents, radiotherapy, or other nonprotocol antitumor therapy",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}